What this pack is
Coreg is the brand name in this record; carvedilol is the generic name. Read both together with the dosage form (oral capsule).
PACK CHECK · MARKET FIRST
CoregGeneric namecarvedilol
How this medicine works
The U.S. COREG label describes carvedilol as having alpha-1 blocking and nonselective beta-adrenergic blocking activity. This helps explain why heart rate, blood pressure, cardiac function, respiratory status, diabetes and the complete medicine list need joint review; it does not predict individual benefit, tolerance, tablet count, suitability, need for genetic testing or a plan to combine with another medicine.
Read source: United States ↗Current regulatory record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- Coreg
- Generic name
- carvedilol
- Dosage-form class
- Immediate-release oral film-coated tablets: 3.125 mg, 6.25 mg, 12.5 mg and 25 mg; not merged with COREG CR extended-release capsules
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
4 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed page updated 31 Jul 2026; SPL v3 published 3 Aug 2026
Carvedilol 3.125 mg per tablet; 100-tablet bottle
- Product code
- NDC 80725-139-20
- Form and route
- COREG carvedilol immediate-release oral film-coated tablet · oral
- Container
- bottle
- carvedilol
- 3.125 mglabelled amount per tablet; not an individual tablet-count, adjustment, splitting or switching rule
- Package
- 100 tablets per bottle
- Labelled appearance
- orange strength band · white oval film-coated tablet · imprint 39 / WPNot scored in this labelled presentation
United States label · DailyMed page updated 31 Jul 2026; SPL v3 published 3 Aug 2026
Carvedilol 6.25 mg per tablet; 100-tablet bottle
- Product code
- NDC 80725-140-20
- Form and route
- COREG carvedilol immediate-release oral film-coated tablet · oral
- Container
- bottle
- carvedilol
- 6.25 mglabelled amount per tablet; not an individual tablet-count, adjustment, splitting or switching rule
- Package
- 100 tablets per bottle
- Labelled appearance
- green strength band · white oval film-coated tablet · imprint 4140 / WPScored appearance; this is not a self-splitting instruction
United States label · DailyMed page updated 31 Jul 2026; SPL v3 published 3 Aug 2026
Carvedilol 12.5 mg per tablet; 100-tablet bottle
- Product code
- NDC 80725-141-20
- Form and route
- COREG carvedilol immediate-release oral film-coated tablet · oral
- Container
- bottle
- carvedilol
- 12.5 mglabelled amount per tablet; not an individual tablet-count, adjustment, splitting or switching rule
- Package
- 100 tablets per bottle
- Labelled appearance
- red strength band · white oval film-coated tablet · imprint 4141 / WPScored appearance; this is not a self-splitting instruction
United States label · DailyMed page updated 31 Jul 2026; SPL v3 published 3 Aug 2026
Carvedilol 25 mg per tablet; 100-tablet bottle
- Product code
- NDC 80725-142-20
- Form and route
- COREG carvedilol immediate-release oral film-coated tablet · oral
- Container
- bottle
- carvedilol
- 25 mglabelled amount per tablet; not an individual tablet-count, adjustment, splitting or switching rule
- Package
- 100 tablets per bottle
- Labelled appearance
- purple strength band · white oval film-coated tablet · imprint 4142 / WPScored appearance; this is not a self-splitting instruction
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
COREG label reading: four mg values identify distinct regular tablets, not a self-adjustment ladder
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the current U.S. DailyMed public label to check COREG, carvedilol, 3.125/6.25/12.5/25 mg per tablet, regular oral-tablet form, exact NDC and 100-tablet bottle. It does not decide an individual's tablet count, when to start or stop, whether to split, use with another cardiovascular product, or how to change from COREG CR.
- Check COREG, carvedilol, mg per tablet, regular oral-tablet form, actual NDC, bottle count and target market together. Milligrams describe the labelled amount in an exact tablet, not a web rule for personal tablet count, adjustment or replacing one pack with another.
- COREG CR is an extended-release capsule with a different dosage form and labelled ingredient form from the regular tablets on this page. Do not self-convert, combine, separate, alternate or substitute based on a shared brand, similar numbers or a claim about frequency; have the exact packs and full medicine list reviewed by a pharmacist or prescriber.
- The current label flags abrupt discontinuation, slow heart rate, low blood pressure, heart failure/fluid retention, masking of low-glucose symptoms in diabetes, and review cues with digoxin, amiodarone, verapamil/diltiazem-type products, blood-pressure medicines and glucose-lowering medicines. These do not let a webpage decide whether products can be used together, which to stop first or how to separate them.
- With fainting, marked dizziness, chest pain, breathing difficulty, a clearly abnormal heart rate, rapid change in weight or swelling, altered consciousness or another acute severe problem, prioritise local urgent medical support; do not wait for a website search, abruptly self-stop, or try to counteract it with another cardiovascular pack.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. COREG carvedilol public label (Waylis Therapeutics; SPL v3, published 3 Aug 2026) ↗Current regulatory record · reviewed 2026-08-20
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Coreg (carvedilol). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Coreg is the brand in this record and carvedilol is the active-ingredient name. Check both with the dosage form (Immediate-release oral film-coated tablets: 3.125 mg, 6.25 mg, 12.5 mg and 25 mg; not merged with COREG CR extended-release capsules) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
CO-MEDICATION REVIEW · NOT A TREATMENT DECISION
When LANOXIN / digoxin is on the same list: review the complete medicine list first
The current U.S. COREG public label names digoxin as a co-medication cue requiring review and notes that both can affect atrioventricular conduction and heart rate. This card only signals that every actual pack, OTC product, supplement and recent symptom should be reviewed by a pharmacist or prescriber; it does not decide co-use or advise self-stopping, time-separation, replacement or adjustment of either medicine.
Open the Lanoxin / digoxin record →
Add both records to this device's family medicine list →
Open the primary source for this co-medication review cue ↗Current regulatory record · reviewed 2026-08-20HOW IT WORKS · NOT A TREATMENT PLAN
How carvedilol works: it has alpha-1 and beta-adrenergic blocking activity
- “Alpha/beta blocking” is a mechanism pathway, not a web tool for deciding which medicine causes a person's heart rate, blood pressure, chest symptoms, fatigue or dizziness. Any new symptom, test or monitoring issue needs professional review with the exact product, condition and complete medicine list.
- When another product affects heart rate, conduction, blood pressure, glucose or fluid status, a different class, shared cardiovascular use or a different-looking pack does not prove combination is safe. In particular, digoxin, amiodarone, certain calcium-channel blockers, blood-pressure medicines, glucose-lowering medicines and OTC/supplement products should be reviewed together with the actual packs.
- Mechanism does not replace item-by-item checking of extended-release capsules versus regular tablets, different strengths, target market, prior reactions and the full medicine list. For a contemplated start, stop, adjustment, form change, tablet splitting or a new concerning symptom, contact a local pharmacist or clinician promptly.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. COREG carvedilol public label (Waylis Therapeutics; SPL v3, published 3 Aug 2026) ↗Current regulatory record · reviewed 2026-08-20
- FDA: COREG (carvedilol) NDA 020297 historical approval material ↗Historical public record · reviewed 2026-08-20
- FDA Drugs@FDA official search entry ↗Official lookup entry · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
Coregcarvedilol
This page links to public primary-source material for Coreg. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The current COREG label lists Initial U.S. Approval: 1995. This year only locates the U.S. label and historical application material linked on this page; it does not establish approval, holder, supply, sale eligibility, originator/generic relationship or individual suitability in Mainland China, the EU, Japan or another market.
DailyMed (NLM): current U.S. COREG carvedilol public label (Waylis Therapeutics; SPL v3, published 3 Aug 2026) ↗Current DailyMed SPL v3 published
The DailyMed media catalogue lists current COREG SPL v3 as published on 3 Aug 2026; the page update date is 31 Jul 2026. This page separately displays four exact 100-tablet bottle panels and does not establish actual stock, purchase, individual tablet count, conversion to COREG CR or another-market status.
DailyMed (NLM): current U.S. COREG carvedilol public label (Waylis Therapeutics; SPL v3, published 3 Aug 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current public label and four exact 100-tablet bottle panels linkedThe panels correspond respectively to NDC 80725-139-20 (3.125 mg), 80725-140-20 (6.25 mg), 80725-141-20 (12.5 mg) and 80725-142-20 (25 mg). They do not authenticate a product or establish actual availability, stock, purchase, individual tablet count, splitting, discontinuation, co-use or interchangeability.
Mainland China, EU, Japan and other markets
Market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the U.S. label, NDC or brand name; every market needs separate checking against current local regulatory information.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Can regular COREG tablets and COREG CR extended-release capsules be self-converted by milligrams or dosing frequency?
No. The brand, generic name, milligrams, NDC and package information for the regular tablets on this page only help identify the exact product. The extended-release capsule is a different dosage-form and label layer; do not self-convert, substitute, combine or stop based on a shared brand, similar numbers or a photo. Take both actual packs, the prescription and complete medicine list to a pharmacist or prescriber for review.
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.